A Phase 3 interventional study of Lenalidomide and Rituximab in Lymphoma, Non-Hodgkin, sponsored by Celgene. Completed at 126 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing lenalidomide in Lymphoma, Mantle-Cell — 5 open to participants now, 8 under way, none of them phase 3. Lenalidomide · Lymphoma, Mantle-Cell.
Among the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell, this one is the 2nd largest by enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2014, is one of 4 in phase 3, and was the 24th registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →5 of the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
Peking University Third Hospital · Sites in China
Ages 18–80
Academic and Community Cancer Research United · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–80
City of Hope Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 30 · Phase 3 4
First in 2002; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 503 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 39 across the 43 interventional studies. Of the 31 that completed or were terminated, 16 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
13 studies in Lymphoma, Mantle-Cell by Bristol-Myers Squibb: 1 open now, 1 under way, none of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 13 studies in Lymphoma, Mantle-Cell by Bristol-Myers Squibb, this one is the only one that started in 2014, is one of 2 in phase 3, and was the 6th registered.
Bristol-Myers Squibb’s Lymphoma, Mantle-Cell studies by the year they started, since 2007.
4 of the studies testing lenalidomide in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06504199Institute of Hematology & Blood Diseases Hospital, ChinaObinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma | 2026-12-31 |
| NCT05861050City of Hope Medical CenterGlofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | 2027-02-01 |
| NCT03523975City of Hope Medical CenterVenetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | 2027-06-24 |
| NCT07261163Institute of Hematology & Blood Diseases Hospital, ChinaObinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell, from their registry updates:
Among Bristol-Myers Squibb’s 13 in Lymphoma, Mantle-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is an immunomodulatory agent with direct and immune-mediated mechanisms of action, as well as clinical activity in NHL. Recent studies in frontline and relapsed/refractory NHL show high activity for lenalidomide plus rituximab (R2), supporting further study of this combination.
MAGNIFY (NCT01996865) is a phase 3b, multicenter, open-label study of patients with grades 1-3b or transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL) who received ≥1 prior therapy and had stage I-IV, measurable disease. \~500 patients are planned for enrollment in 12 cycles of R2 induction, with a projected \~314 patients with ≥SD after induction randomized (1:1) to two maintenance arms. Induction includes oral lenalidomide 20 mg/day, days 1-21 per 28-day cycle (d1-21/28) plus IV rituximab 375 mg/m2, days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 3, 5, 7, 9, and 11 (28-day cycles). Patients are then randomized to maintenance lenalidomide 10 mg/day, d1-21/28, cycles 13-30, plus rituximab 375 mg/m2, day 1 of cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 (R2, Arm A), or rituximab alone (same schedule, Arm B). Patients receiving R2 maintenance after 18 cycles may continue maintenance lenalidomide monotherapy 10 mg/day, d1-21/28 (per patient and/or investigator discretion), until disease progression as tolerated. The primary endpoint is progression-free survival (per modified 1999 IWG criteria). Secondary endpoints include safety, overall survival, response rates, duration of response, and quality of life (exploratory). Patients will be followed for ≥5 years after the last patient initiated induction therapy. Enrollment in MAGNIFY began in March 2014; as of Jan 2016, 133 patients are enrolled.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
This study's enrollment of 503 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Browse Lymphoma, Mantle-Cell studies →Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted before Celgene became part of Bristol-Myers Squibb.
Compared within Lymphoma, Mantle-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-- Age ≥18 years
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction Period (12 cycles): Lenalidomide 20mg (10 mg if creatinine clearance ≥ 30 mL/min but \< 60mL/min) by mouth (PO) daily (QD) on Days 1 to 21 of every 28-day cycle during cycles 1 through 12 and rituximab 375mg/m\^2 intraveneously (IV) every week in Cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period (lasting 18 Cycles) that includes Lenalidomide 10 mg PO QD on Days 1 to 21 of every 28-day cycle during cycles 13 to 30 and rituximab 375 mg/m\^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 followed by an optional Maintenance Period (up to Progressive Disease) receiving Lenalidomide 10mg PO QD on Days 1 through 21 of every 28 day cycle until the disease progresses
Drug: Lenalidomide · Drug: Rituximab
Induction Period (12 Cycles): Lenalidomide 20 mg PO QD (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) on Days 1 to 21 of every 28-day cycle during cycles 1 to 12 and rituximab 375 mg/m\^2 IV every week in cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period for 18 Cycles that includes: Rituximab 375 mg/m\^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29
Drug: Lenalidomide · Drug: Rituximab
Also known as: CC-5013, Revlimid
Also known as: Rituxan
Progression Free Survival (PFS)
Progression free survival (PFS) is defined as the time from the date of first dose of maintenance therapy to the date of the first objective documentation of tumor progression or death due to any cause. Analysis was based on Kaplan Meier estimates. The PFS events were determined using a modification of the IWG 1999 criteria.
Time frame: From the first dose date of maintenance therapy to objective disease progression or death from any cause, whichever occurs first (up to approximately 432 weeks)
Overall Survival (OS)
Overall Survival (OS) is defined as the time between the first dose date of maintenance therapy and death from any cause. Participants who complete the study and are still alive at the time of the clinical data cutoff date will be censored at the last visit date or the last contact date, whichever is later. Participants who were lost to follow-up prior to the clinical data cut-off date will also be censored at the time of the last contact. Analysis was based on Kaplan Meier estimates and Hazard Ratio (HR).
Time frame: From the first dose date of maintenance therapy to death from any cause (up to approximately 480 weeks)
Improvement of Response (IOR)
Improvement of Response (IOR) is the percentage of participants with improved tumor response during the maintenance phase (converted from partial response at end of induction to complete response or complete response unconfirmed as best response) and participants who converted from stable disease at the end of induction period to partial response or better as best response during maintenance phase.
Time frame: From the first dose date of maintenance therapy to death from any cause (up to approximately 432 weeks)
Overall Response Rate (ORR)
The overall response rate (ORR) is defined as the percentage of participants with a best response of at least partial response (including complete response, complete response unconfirmed and partial response) after the first dose date of maintenance therapy and prior to any treatment change.
Time frame: From the first dose date of maintenance therapy up to CR, CRu, PR, or treatment change (up to approximately 432 weeks)
Complete Response Rate (CRR)
Best Complete Response Rate (CRR), defined as the proportion of participants with a best response of at least CRu (including CR and CRu) after the first dose date of maintenance therapy and prior to any treatment change.
Time frame: From the first dose date of maintenance therapy up to CR or CRu (up to approximately 432 weeks)
Duration of Response (DOR)
DOR is from initial response (at least CRu) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death. Participants who have not progressed or died at the time of the clinical data cutoff date will be censored at the last assessment showing no progression. Participants who change treatment without evidence of disease progression will be censored at the last assessment showing no progression prior to treatment change. Analysis was based on Kaplan Meier estimates.
Time frame: From the initial response (at least PR) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death, whichever occurs first (up to approximately 432 weeks)
Time to Next Anti-lymphoma Treatment
Time to next anti-lymphoma treatment is defined as the time from the first dose date of maintenance therapy to the time of first documented administration of new anti-lymphoma therapy. Participants without new treatment therapy will be censored at the last visit. Analysis was based on Kaplan Meier estimates.
Time frame: From the first dose date of maintenance therapy to the time of first documented administration of new anti-lymphoma therapy (up to approximately 300 weeks)
Time to Histological Transformation
Time to histological transformation is defined as from the first dose date of maintenance therapy to the time of histological transformation as measured based on documentation of histological transformation (as assessed by the investigator). Analysis was based on Kaplan Meier estimates. In case of clinical suspicion of transformation, including rapid disease progression, unexpected changes in "B" symptoms or rapidly increasing LDH, a biopsy should be performed. In this clinical trial, histological transformation will be considered disease progression. This endpoint will not be calculated for participants randomized with transformed Follicular Lymphoma (tFL).
Time frame: From the first dose date of maintenance therapy to the time of histological transformation (up to approximately 432 weeks)
Duration of Complete Response (DOCR)
Duration of complete response (DOCR) is calculated as the time from the initial response (CR or CRu) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death. Analysis was based on Kaplan Meier estimates. Participants who have not progressed or died at the time of the clinical data cutoff date will be censored at the last assessment showing no progression. Participants who change treatment without evidence of disease progression will be censored at the last assessment showing no progression prior to treatment change.
Time frame: From the initial CR/CRu after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death, whichever occurs first (up to approximately 432 weeks)
Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
Number of participants experiencing AEs, SAEs, AEs leading to study discontinuation, and AEs of interest (AEIs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect. TEAEs are defined as AEs with an onset date on or after the first dose of study treatment up to 30 days after the last dose of study treatment in the study, or if a pre-existing condition worsens in severity or becomes serious after receiving the first dose of study treatment.
Time frame: From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)
Participants Experiencing Adverse Events Related to Vital Signs
The number of participants who experienced adverse events related to vital sign measurements
Time frame: From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)
Participants With Grade 3 or Grade 4 Hematology Parameters
Clinical laboratory values in induction period include any laboratory values that are taken after the first dose date of induction therapy through 28 days after the last dose date of induction therapy or before the first dose date of maintenance therapy, whichever is earlier. Graded according to the NCI CTCAE version 4.03, except for tumor flare reaction, which is accessed using NCI CTCAE version 3.0. Participants with zero maximum grade are excluded.
Time frame: From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)
Participants With Grade 3 or Grade 4 Serum Chemistry Parameters
Clinical laboratory values in induction period include any laboratory values that are taken after the first dose date of induction therapy through 28 days after the last dose date of therapy. Graded according to the NCI CTCAE version 4.03, except for tumor flare reaction, which is accessed using NCI CTCAE version 3.0. Participants with zero maximum grade are excluded.
Time frame: From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)
| Milestone | Induction Period: Lenalidomide + Rituximab | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|---|
| Started | 503 | 0 | 0 |
| Treated | 500 | 0 | 0 |
| Completed | 284 | 0 | 0 |
| Not completed | 219 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Progressive disease | 4 | 0 | 0 |
| Withdrew: Lost to follow-up | 10 | 0 | 0 |
| Withdrew: Other reasons | 13 | 0 | 0 |
| Withdrew: Adverse event | 20 | 0 | 0 |
| Withdrew: Withdrawal by subject | 60 | 0 | 0 |
| Withdrew: Death | 111 | 0 | 0 |
| Milestone | Induction Period: Lenalidomide + Rituximab | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|---|
| Started | 0 | 135 | 132 |
| Treated | 0 | 134 | 132 |
| Completed | 0 | 78 | 89 |
| Not completed | 0 | 57 | 43 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Other reasons | 0 | 8 | 5 |
| Withdrew: Progressive disease | 0 | 6 | 23 |
| Withdrew: Withdrawal by subject | 0 | 18 | 4 |
| Withdrew: Adverse event | 0 | 7 | 7 |
| Withdrew: Death | 0 | 15 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
Progression free survival (PFS) is defined as the time from the date of first dose of maintenance therapy to the date of the first objective documentation of tumor progression or death due to any cause. Analysis was based on Kaplan Meier estimates. The PFS events were determined using a modification of the IWG 1999 criteria.
| Weeks | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|
| Progression Free Survival (PFS) | 263.1 (166.1 to NA) | 229.1 (173.7 to NA) |
Overall Survival (OS) is defined as the time between the first dose date of maintenance therapy and death from any cause. Participants who complete the study and are still alive at the time of the clinical data cutoff date will be censored at the last visit date or the last contact date, whichever is later. Participants who were lost to follow-up prior to the clinical data cut-off date will also be censored at the time of the last contact. Analysis was based on Kaplan Meier estimates and Hazard Ratio (HR).
| Weeks | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|
| Overall Survival (OS) | NA (439.4 to NA) | NA (395.7 to NA) |
Improvement of Response (IOR) is the percentage of participants with improved tumor response during the maintenance phase (converted from partial response at end of induction to complete response or complete response unconfirmed as best response) and participants who converted from stable disease at the end of induction period to partial response or better as best response during maintenance phase.
| Percentage of participants | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|
| Improvement of Response (IOR) | 20 (13.6 to 27.7) | 11.4 (6.5 to 18.0) |
The overall response rate (ORR) is defined as the percentage of participants with a best response of at least partial response (including complete response, complete response unconfirmed and partial response) after the first dose date of maintenance therapy and prior to any treatment change.
| Percentage of participants | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|
| Overall Response Rate (ORR) | 85.2 (78.1 to 90.7) | 79.5 (71.7 to 86.1) |
Best Complete Response Rate (CRR), defined as the proportion of participants with a best response of at least CRu (including CR and CRu) after the first dose date of maintenance therapy and prior to any treatment change.
| Percentage of participants | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|
| Complete Response Rate (CRR) | 60.7 (52.0 to 69.0) | 58.3 (49.4 to 66.8) |
DOR is from initial response (at least CRu) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death. Participants who have not progressed or died at the time of the clinical data cutoff date will be censored at the last assessment showing no progression. Participants who change treatment without evidence of disease progression will be censored at the last assessment showing no progression prior to treatment change. Analysis was based on Kaplan Meier estimates.
| Weeks | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|
| Duration of Response (DOR) | 268.3 (168.0 to NA) | 306.0 (183.7 to NA) |
Time to next anti-lymphoma treatment is defined as the time from the first dose date of maintenance therapy to the time of first documented administration of new anti-lymphoma therapy. Participants without new treatment therapy will be censored at the last visit. Analysis was based on Kaplan Meier estimates.
| Weeks | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|
| Time to Next Anti-lymphoma Treatment | NA (300.4 to NA) | NA (283.4 to NA) |
Time to histological transformation is defined as from the first dose date of maintenance therapy to the time of histological transformation as measured based on documentation of histological transformation (as assessed by the investigator). Analysis was based on Kaplan Meier estimates. In case of clinical suspicion of transformation, including rapid disease progression, unexpected changes in "B" symptoms or rapidly increasing LDH, a biopsy should be performed. In this clinical trial, histological transformation will be considered disease progression. This endpoint will not be calculated for participants randomized with transformed Follicular Lymphoma (tFL).
| Weeks | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|
| Time to Histological Transformation | NA (NA to NA) | NA (NA to NA) |
Duration of complete response (DOCR) is calculated as the time from the initial response (CR or CRu) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death. Analysis was based on Kaplan Meier estimates. Participants who have not progressed or died at the time of the clinical data cutoff date will be censored at the last assessment showing no progression. Participants who change treatment without evidence of disease progression will be censored at the last assessment showing no progression prior to treatment change.
| Weeks | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|
| Duration of Complete Response (DOCR) | 298.0 (176.0 to NA) | NA (221.1 to NA) |
Number of participants experiencing AEs, SAEs, AEs leading to study discontinuation, and AEs of interest (AEIs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect. TEAEs are defined as AEs with an onset date on or after the first dose of study treatment up to 30 days after the last dose of study treatment in the study, or if a pre-existing condition worsens in severity or becomes serious after receiving the first dose of study treatment.
| Participants | Induction Period: Lenalidomide + Rituximab | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|---|
| Participants experiencing at least one TEAE | 499 | 133 | 120 |
| Participants experiencing at least one serious TEAE | 172 | 57 | 22 |
The number of participants who experienced adverse events related to vital sign measurements
| Participants | Induction Period: Lenalidomide + Rituximab | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|---|
| Hypertension | 34 | 9 | 6 |
| Hypotension | 22 | 4 | 5 |
| Hypoxia | 5 | 2 | 0 |
Clinical laboratory values in induction period include any laboratory values that are taken after the first dose date of induction therapy through 28 days after the last dose date of induction therapy or before the first dose date of maintenance therapy, whichever is earlier. Graded according to the NCI CTCAE version 4.03, except for tumor flare reaction, which is accessed using NCI CTCAE version 3.0. Participants with zero maximum grade are excluded.
| Participants | Induction Period: Lenalidomide + Rituximab | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|---|
| Anemia - Grade 3 | 31 | 7 | 0 |
| Leukopenia - Grade 3 | 101 | 19 | 6 |
| Thrombocytopenia - Grade 3 | 29 | 2 | 1 |
| Neutropenia - Grade 3 | 103 | 24 | 10 |
| Lymphopenia - Grade 3 | 126 | 31 | 21 |
| Anemia - Grade 4 | 0 | 0 | 0 |
| Leukopenia - Grade 4 | 17 | 5 | 0 |
| Thrombocytopenia - Grade 4 | 7 | 0 | 0 |
| Neutropenia - Grade 4 | 94 | 25 | 6 |
| Lymphopenia - Grade 4 | 20 | 10 | 2 |
Clinical laboratory values in induction period include any laboratory values that are taken after the first dose date of induction therapy through 28 days after the last dose date of therapy. Graded according to the NCI CTCAE version 4.03, except for tumor flare reaction, which is accessed using NCI CTCAE version 3.0. Participants with zero maximum grade are excluded.
| Participants | Induction Period: Lenalidomide + Rituximab | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|---|
| Hypokalemia - Grade 3 | 30 | 8 | 4 |
| Hyperkalemia- Grade 3 | 4 | 0 | 1 |
| Hypocalcemia - Grade 3 | 7 | 1 | 0 |
| Hypercalcemia - Grade 3 | 7 | 0 | 0 |
| Hypophosphatemia - Grade 3 | 17 | 6 | 2 |
| Hypercreatininemia - Grade 3 | 3 | 1 | 0 |
| Hyperuricemia - Grade 3 | 40 | 13 | 20 |
| Alanine Aminotransferase Increased - Grade 3 | 14 | 3 | 0 |
| Aspartate Aminotransferase Increased - Grade 3 | 9 | 1 | 0 |
| Hyperbilirubinemia - Grade 3 | 5 | 3 | 1 |
| Hypokalemia - Grade 4 | 4 | 0 | 0 |
| Hyperkalemia- Grade 4 | 1 | 2 | 0 |
| Hypocalcemia - Grade 4 | 5 | 5 | 2 |
| Hypercalcemia - Grade 4 | 3 | 5 | 0 |
| Hypophosphatemia - Grade 4 | 1 | 1 | 1 |
| Hypercreatininemia - Grade 4 | 1 | 2 | 0 |
| Hyperuricemia - Grade 4 | 9 | 4 | 0 |
| Alanine Aminotransferase Increased - Grade 4 | 0 | 0 | 0 |
| Aspartate Aminotransferase Increased - Grade 4 | 0 | 0 | 0 |
| Hyperbilirubinemia - Grade 4 | 1 | 1 | 0 |
Collected over Participants were assessed for all-cause mortality from their first dose of study treatment to study completion, (up to approximately 10 years). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Period: Lenalidomide + Rituximab | 112/500 (22.4%) | 172/500 (34.4%) | 491/500 (98.2%) |
| Arm A: Lenalidomide + Rituximab | 26/134 (19.4%) | 57/134 (42.5%) | 129/134 (96.3%) |
| Arm B: Rituximab | 32/132 (24.2%) | 22/132 (16.7%) | 106/132 (80.3%) |
| Event | Induction Period: Lenalidomide + Rituximab | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/500 | 10/134 | 5/132 |
| PneumoniaInfections and infestations | 18/500 | 8/134 | 1/132 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/500 | 5/134 | 1/132 |
| NeutropeniaBlood and lymphatic system disorders | 15/500 | 3/134 | 0/132 |
| Febrile neutropeniaBlood and lymphatic system disorders | 14/500 | 1/134 | 1/132 |
| Atrial fibrillationCardiac disorders | 9/500 | 3/134 | 0/132 |
| PyrexiaGeneral disorders | 1/500 | 3/134 | 2/132 |
| BronchitisInfections and infestations | 1/500 | 3/134 | 0/132 |
| CellulitisInfections and infestations | 5/500 | 3/134 | 0/132 |
| Urinary tract infectionInfections and infestations | 3/500 | 3/134 | 0/132 |
| Event | Induction Period: Lenalidomide + Rituximab | Arm A: Lenalidomide + Rituximab | Arm B: Rituximab |
|---|---|---|---|
| FatigueGeneral disorders | 225/500 | 27/134 | 15/132 |
| NeutropeniaBlood and lymphatic system disorders | 217/500 | 54/134 | 22/132 |
| DiarrhoeaGastrointestinal disorders | 176/500 | 56/134 | 11/132 |
| CoughRespiratory, thoracic and mediastinal disorders | 103/500 | 41/134 | 20/132 |
| NauseaGastrointestinal disorders | 150/500 | 15/134 | 6/132 |
| ConstipationGastrointestinal disorders | 146/500 | 12/134 | 2/132 |
| PruritusSkin and subcutaneous tissue disorders | 96/500 | 2/134 | 3/132 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 68/500 | 23/134 | 18/132 |
| Upper respiratory tract infectionInfections and infestations | 65/500 | 22/134 | 14/132 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 82/500 | 6/134 | 1/132 |
All participants started in the induction and maintenance periods and are accounted for in this arm.
| Age, Categorical(Participants) | Overall Study |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 209 |
| >=65 years | 294 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 215 |
| Male | 288 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 33 |
| Not Hispanic or Latino | 463 |
| Unknown or Not Reported | 7 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 17 |
| White | 468 |
| More than one race | 0 |
| Unknown or Not Reported | 12 |
Showing the first 100 of 126 sites across 3 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2014 to primary completion in May 2024, 121 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 121 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenalidomide · Rituximab